GET DAILY SIGNALSGlaukos (GKOS) Shares Climb +47% in 30 Days After Earnings Beat
Key Takeaways
- Glaukos (GKOS) shares climbed roughly 47% over the trailing 30 days, from $167.89 on October 14 to $246.03 on November 12, powered by a third-quarter earnings report that far exceeded Wall Street expectations.
- Third-quarter 2026 net sales rose 58% year over year to $211.0 million, topping the consensus estimate of about $168 million by more than 25%.
- Management raised full-year 2026 revenue guidance to $775 million–$785 million and introduced preliminary 2027 revenue guidance of $1 billion.
- The rally was led by two growth drivers: the iDose TR glaucoma implant (about $76 million in quarterly sales) and the Epioxa corneal cross-linking therapy (about $53 million).
- Several analysts raised price targets after the report, including Needham to $251 and BTIG to $234, while Stifel and Mizuho lifted theirs to $225.
- For additional detail on this ticker, explore our pages on Price Targets, Earnings, and Forecast.
- You can also monitor the stock with Trending AI Robots.
Company Overview and Market Position
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company focused on glaucoma, corneal disorders, and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery (MIGS), launching its first MIGS device in 2012, and markets the iStent family of surgical glaucoma devices. Its flagship growth products include iDose TR, a first-of-its-kind long-duration intracameral implant that delivers continuous glaucoma drug therapy inside the eye, and Epioxa, the only FDA-approved epithelium-on corneal cross-linking therapy for keratoconus. Investors follow GKOS for its transition toward "dropless" therapies that reduce reliance on daily eye drops, its expanding pipeline across glaucoma, corneal, and retinal platforms, and its push to become a diversified leader in ophthalmology. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance Over the Last 30 Days and Quarter
Over the last 30 days, GKOS has advanced about 46.5%, moving from a closing price of $167.89 on October 14 to $246.03 on November 12. The move was concentrated in a single session: on October 29, the stock surged roughly 33.6% after third-quarter results, its sharpest one-day gain in years, before consolidating near record levels in early November.
The quarterly picture shows a stronger but less linear trend. From a closing level of $186.63 on August 12, the stock has risen about 32% to $246.03 on November 12. That gain masked a notable pullback, with shares sliding toward $153 in late September before the earnings-driven re-rating pushed the stock to new all-time highs.
What Drove the Recent Price Move
The primary catalyst was Glaukos's third-quarter earnings report, released on October 28. Net sales jumped 58% year over year to $211.0 million, and non-GAAP earnings per share came in at $0.47 versus an expected loss of $0.10. The company also swung to a small GAAP net profit of $2.0 million from a year-earlier loss, while gross margin expanded to roughly 85% on a GAAP basis and 88% on a non-GAAP basis.
Guidance was the bigger story. Glaukos raised its 2026 revenue outlook to $775 million–$785 million, up $90 million at the midpoint from a prior range of $680 million–$700 million, and introduced preliminary 2027 revenue guidance of $1 billion. Analysts responded by raising targets: Needham lifted its price target from $201 to $251, BTIG from $205 to $234, and Stifel from $190 to $225, while Mizuho raised its fair value to $225. Positive Phase IV data showing meaningful intraocular pressure reduction for iDose TR combined with cataract surgery added further support to the clinical story. From what I see, these revisions reflect growing confidence in the growth trajectory.
Broader Quarterly Drivers Behind the Advance
Across the broader three-month period, GKOS's advance has been anchored in accelerating commercial execution rather than a single event. The iDose TR implant continued to scale, with U.S. Glaucoma sales up 47% year over year in the third quarter, while the Epioxa launch gained momentum following the July 1 effective date of its product-specific J-code, helping drive Corneal Health sales up 154%. Institutional positioning also strengthened, with hedge fund holdings rising notably earlier in the year. A September pullback reflected broader market choppiness and lingering uncertainty around potential Medicare local coverage determinations for iDose TR, but the company's stronger-than-expected results and raised outlook refocused investor attention on its growth trajectory. I’m watching this closely as the commercial momentum builds.
Key Factors to Monitor Going Forward
Looking ahead, investors will monitor whether U.S. Glaucoma and Corneal Health franchises sustain their sequential growth, given that both carry the company's guidance. A key risk is the potential finalization of Medicare local coverage determinations for iDose TR, which management has said it has factored into its 2027 outlook. Epioxa's payer access and prior-authorization timelines, along with operating expense growth and gross margin trajectory, will also matter. Further pipeline milestones, including progress toward a targeted FDA approval for iDose TRIO by the end of 2027 and advancement of the retinal and corneal programs, could shape the longer-term narrative.
Using AI Tools to Track Momentum
In my analysis of names like this, I often turn to Tickeron’s AI Trading Bots to test automated strategies across different timeframes and see how they align with the fundamentals. The platform offers a range of bots focused on momentum and swing approaches, which can help compare performance metrics side by side for ideas on execution. Past performance does not guarantee future results, but it provides another lens for research when evaluating opportunities in ophthalmology stocks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
GKOS in upward trend: 10-day moving average moved above 50-day moving average on October 26, 2026
The 10-day moving average for GKOS crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
GKOS moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +8.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where GKOS advanced for three days, in 248 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 252 of 314 cases where GKOS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The 10-day RSI Indicator for GKOS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In 35 of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GKOS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
GKOS broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 14 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. GKOS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.395) is normal, around the industry mean (4.142). P/E Ratio (-68.627) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (12.570) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (15.456) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an ophthalmic medical device company
Industry MedicalNursingServices
Advertisement